Talecris Biotherapeutics

(today Grifols International SA)

CONSULTING (a Capricorn Consilium Project)

Wanted: Biotech consultant and country specialist for market entrance study in the field of plasma products.

The Client

Grifols is a global healthcare company which produces life-saving protein therapies. Its Bioscience division is dedicated to hemotherapy and the treatment of medical conditions using blood or blood components made from human plasma. In 2011, Grifols acquired and integrated Talecris.


The Assignment

Talecris was evaluating several expansion scenarios, for which market entrance studies were required. Capricorn Consilium was predestinated to conduct such task for a certain country and got assigned.

The Solution

Compilation of a classical market access  study: check of the total market as well as of its relevant segments, competitors, products, prices, sales, purchasing, consumers etc. Internet research and telephone calls were supplemented by face-to-face interviews with relevant hospital pharmacists, purchase managers and chief physicians. The result was an extended proposal of several market access strategies, as well as concrete suggestions to put the strategies into action, all of which were relevant to Talecris for their decision making.